Day 2 - Friday 24th May 2024

10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe

Trends and Strategies to Optimise Value and Patient Access

Hilton London Kensington, London, UK

CHALLENGES & OPPORTUNITIES

  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship

Moderator:
Alexander Bastian, VP, Value & Market Access, AM-Pharma

Panelist:
Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Nicki K Catterick, Vice President, Global Value and Access Oncology, IPSEN
Eirini Palaka, Vice President, Global Value & Access, Rare Disease, IPSEN

  • What are the implications of the new EU HTA procedure?
  • What to expect from Joint Scientific Consultations and Joint Clinical Assessments?
  • How can companies best prepare for JCA, starting 12 January 2025?

Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE

  • Access to innovative medicines remains a key issue worldwide
  • Limitations of the some of the initiatives to address this such as the EUnetHTA JCA and the expected change in legislation in Europe
  • How can pharmaceutical companies and health authorities work together to bridge the gap
  • The benefit of a comprehensive landscape analyses
  • The role of an Advisory Board
  • The value of consensus in HTA where there is uncertainty.
  • Influencing the right stakeholders
  • Plasma-derived medicines (PDMPs) are essential for some 300,000 patients across the EU who rely on these therapies every day to treat a variety of rare, chronic, and life-threatening conditions. Without these treatments, many patients would have a substantially diminished quality of life, and some may not survive.
  • PDMPs are a finite resource because the manufacture of these medicines is dependent on the amounts of human plasma collected.
  • Using the AIFA CTS Innovation Algorithm and the WHO Framework for Appropriate Medical Use, a broad range of Key Opinion leaders, in the field of immunology, neurology, rheumatology and dermatology, debated about the appropriate use of Immunoglobulins for their patients. The discussion was concluded in a Green Paper developed by Vintura.

Maarten Van Baelen, Executive Director, Plasma Protein Therapeutics Association

  • Looking beyond market access to patient access
  • What patients can bring to access and how to support them
  • Collaborating for success in access

Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Lindsay Birrell, Co- CEO, Realise Advocacy, Chair of trustees, Medics 4 Rare Diseases

  • Role of market access within the organization and importance of market access capabilities;
  • Building “market access mindset” for cross-functional business partners;
  • Evolving capabilities for future market access leaders
  • Challenges in drug pricing and reimbursement
  • How to navigate a complex balance between financial and strategic risks
  • Strategies to offset regulatory and inflationary pressures.
  • Addressing environmental, social, and corporate governance issues
  • Encouraging cross-functional or cross-company collaborations

Antje Emmermann, Executive Director, Market Access Lead, Alexion

 

  • One of the most overlooked activities in the entire market access flow is tendering, a successful access is measured
    on how the medicine reaches the patients, however an increasing amount of countries are using tenders to add
    additional pressure on the procurement of the therapies, not having an adequate process in place can jeopardize
    access plans and can have unexpected consequences abroad.
  • As innovation brings cancer drugs & curative medicines to the forefront of healthcare systems, how are payers affording to pay for this innovation ?
  • what are the new determinants of value in healthcare, and the geopolitical drivers for value based agreements & innovative contracting ?
  • If the drugs dont work – I want my money back! – access into a global tracker of over 700 innovative contracts from around the globe
  • Who’s shifting the paradigm – adoption curves for those manufacturers leading the way in capabilities for innovative contracting
  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?

Panelist: 

Day 1 Agenda
Scroll to Top